March 6th, 2025: Federal Judge Blocks Pharmacies from Making Copies of Weight Loss Drugs A federal judge has ruled against compounding pharmacies producing their own versions of Eli Lillys diabetes and weight loss drugs, Zepbound and Mounjaro
For this purpose, we searched Google Scholar, PubMed, EBSCOhost and WEB of Science electronic databases for publications up to September 2025
Hims & Hers Canada chief medical officer Sandy Van said more affordable GLP-1 options make the market "more dynamic" and push prices down across the board, benefiting patients regardless of where they seek care.
[55] Semaglutide acts on these alterations by mitigating adipocyte hypertrophy and limiting excessive lipid storage through the downregulation of lipogenic enzymes such as lipoprotein lipase (LPL) and ANGPTL4
While NABP accreditation is not equivalent to PCAB (Pharmacy Compounding Accreditation Board) accreditation, which is considered the gold standard for compounding pharmacies, it does represent a commitment to quality that goes beyond minimum requirements
